KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other Working Capital Changes: 2010-2025

Historic Other Working Capital Changes for Halozyme Therapeutics (HALO) over the last 15 years, with Sep 2025 value amounting to $20.3 million.

  • Halozyme Therapeutics' Other Working Capital Changes rose 152.80% to $20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.8 million, marking a year-over-year increase of 3703.62%. This contributed to the annual value of -$5.4 million for FY2024, which is 30.70% down from last year.
  • As of Q3 2025, Halozyme Therapeutics' Other Working Capital Changes stood at $20.3 million, which was down 43.66% from $36.1 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Other Working Capital Changes peaked at $43.5 million during Q2 2024, and registered a low of -$38.5 million during Q3 2024.
  • For the 3-year period, Halozyme Therapeutics' Other Working Capital Changes averaged around $4.7 million, with its median value being $1.2 million (2023).
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first slumped by 3,323.84% in 2023, then skyrocketed by 994.47% in 2024.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Other Working Capital Changes stood at $5.0 million in 2021, then plummeted by 205.02% to -$5.3 million in 2022, then surged by 122.68% to $1.2 million in 2023, then crashed by 568.03% to -$5.6 million in 2024, then spiked by 152.80% to $20.3 million in 2025.
  • Its last three reported values are $20.3 million in Q3 2025, $36.1 million for Q2 2025, and $5.0 million during Q1 2025.